IQVIA website | Customer Portal

IQVIA™ Real-World Insights Bibliography

Home

Search criteria

Condition: HIV AIDS

Year -

Key

C = Condition
Y = Year
L = Language
A = Analysis type

Total number of items in this bibliography: 17

Add all to report

Exploring current practice, knowledge, and challenges of sexually transmitted infection/HIV management and pre-exposure prophylaxis among Japanese health care professionals: a cross-sectional web survey
Author(s): Mayuko Kamakura 1, Daisuke Fukuda 1, Naho Kuroishi 1, Dilinuer Ainiwaer 2, Junko Hattori 1 (rwesheorj 2)
Affiliations(s): 1) Medical Affairs, MSD K.K., Tokyo, Japan 2) IQVIA Solutions Japan K.K., Tokyo, Japan
Publication(s): AIDS Patient Care and STDs
Document Type(s): Article,
Countries: Japan,
Click here for the abstract
C: Y:	HIV AIDS, 2023	L: A:	English Survey research,


English demographics and cost of HIV-associated comorbidities in individuals over the age of 35: an investigation using the Hospital Episode Statistics (HES) database
Author(s): Wild L, Smith A, Sathia L, Davies S, Fernandez DP, Lawrence D.
Affiliations(s): 1Gilead Sciences, London, UK, 2IQVIA, London, UK
Publication(s): HIV MEDICINE 2018 Apr 1 (Vol. 19, pp. S76-S77).
Document Type(s): Abstract, Poster,
Countries: England,
Click here for the abstract
C: Y:	HIV AIDS, 2022	L: A:	English Cost consequence, Cost of illness, Database Study, Population Based Study,


Potential Healthcare Resource Use And Associated Costs Of Every 2 months Injectable Cabotegravir+Rilpivirine Long-acting Implementation In The Spanish NHS Vs. Daily Oral HIV Treatments
Author(s): Laura-Amanda Vallejo Aparicio (1), Victoria Neches García (1), Beatriz Hernández (2), Gregorio Casado (3), Ferrán Jodar (3), Marco Pinel (3), Daniel Callejo Velasco (3)
Affiliations(s): (1) GSK, Tres Cantos (Madrid), España; (2) ViiV Healthcare, Tres Cantos (Madrid), España; (3)IQIVA, España
Publication(s): ISPOR Europe 2022; November 6-9, 2022; Virtual and Vienna, Austria
Document Type(s): Poster,
Countries: Spain,
Click here for the abstract
C: Y:	HIV AIDS, Infectious disease, 2022	L: A:	English Burden of illness, Cost analysis, Public Health,


Potential Healthcare Resource Use And Associated Costs Of Every 2 months Injectable Cabotegravir+Rilpivirine Long-acting Implementation In The Spanish NHS Vs. Daily Oral HIV Treatments
Author(s): Laura-Amanda Vallejo Aparicio1 , Victoria Neches García1 , Beatriz Hernández 2 , Gregorio Casado3 , Ferrán Jodar 3 , Marco Pinel 3 , Daniel Callejo Velasco3
Affiliations(s): 1GSK, Tres Cantos (Madrid), España; 2ViiV Healthcare, Tres Cantos (Madrid), España; 3IQIVA, España
Publication(s): ISPOR Europe 2022; November 6-9, 2022; Virtual and Vienna, Austria
Document Type(s): Poster,
Countries: Spain,
Click here for the abstract
C: Y:	HIV AIDS, Infectious disease, 2022	L: A:	English


THE COST OF STIGMA ASSOCIATED WITH HIV- A COST-CONSEQUENCE ANALYSIS TO EVALUATE HIV TESTING AND PREVENTION INTERVENTIONS IN KSA
Author(s): Filemban S1, Elrashied S1, Assiri A1, Hakawi A1, Snehanshu S2, Mansour E3, Vemer P4, Awad N5
Affiliations(s): 1Ministry of Health, Riyadh, Saudi Arabia, 2Gilead Sciences Middle East, Dubai Health Care City, United Arab Emirates, 3Gilead, Dubai, United Arab Emirates, 4Groningen University, Groningen, Netherlands, 5IQVIA, Dubai, United Arab Emirates
Publication(s): 2019-11, ISPOR Europe 2019, Copenhagen, Denmark
Document Type(s): Poster,
Countries: Saudi Arabia,
Click here for the abstract
C: Y:	HIV AIDS, 2019	L: A:	English Predictive analytics, Quality of life,


Economic Burden of HIV Antiretroviral Therapy Adverse Events in the United States.
Author(s): Dekoven M, Makin C, Slaff S, Marcus M, Maiese EM.
Affiliations(s): IMS Health, Fairfax, VA, USA. Yoh Services LLC, Philadelphia, PA, USA. Merck Sharp & Dohme Corp, Whitehouse Station, NJ, USA emaiese@gmail.com
Publication(s): J Int Assoc Provid AIDS Care. 2016 Jan-Feb;15(1):66-76
Document Type(s): Article,
Countries: USA,
Click here for the abstract
C: Y:	HIV AIDS, 2016	L: A:	English Retrospective database analysis,


Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
Author(s): Moeremans K1, Hemmett L2, Hjelmgren J3, Allegri G4, Smets E5
Affiliations(s): 1 IMS Health, Brussels, Belgium 2 Tibotec, Buckinghamshire, UK 3 Janssen-Cilag AB, Stockholm, Sweden 4 Janssen-Cilag SpA, Cologno Monzese, Italy 5 Johnson & Johnson Pharmaceutical Services LLC, Mechelen, Belgium
Publication(s): Pharmacoeconomics, 2010, 28 (Suppl 1): 147-167
Document Type(s): Article,
Countries: Belgium, Italy, Nordic, Sweden, UK,
C: Y:	HIV AIDS, 2010	L: A:	English Cost effectiveness,


Cost-effectiveness of etravirine in Sweden in treatment-experienced HIV-1-infected adults with evidence of NNRTI resistance and ? 3 PI mutations.
Author(s): Moeremans K1, Hjelmgren J2, Martin S3
Affiliations(s): 1 IMS Health, Brussels, Belgium 2 Janssen-Cilag, Birkeöd, Denmark 3 J&J, Mechelen, Belgium
Publication(s): 12th European Aids Conference, 2009, November 11-14, Cologne, Germany ISPOR 12th Annual European Congress, 2009, October 24-27, Paris, France
Document Type(s): Poster,
Countries: Nordic, Sweden,
C: Y:	HIV AIDS, 2009	L: A:	English Cost utility,


Cost effectiveness of darunavir/ritonavir 600/100mg BID in treatment-experienced, LPV/R-naïve, PI-resistent, HIV-infected adults in the United Kingdom, Belgium, Italy and Sweden.
Author(s): Moeremans K, Hemmett L, Hjelmgren J, Allegri G, Smets E
Affiliations(s):
Publication(s): ISPOR 11th Annual International Meeting, 2008, November 8-11, Athens, Greece
Document Type(s): Oral presentation,
Countries: Belgium, Italy, Sweden, UK,
C: Y:	HIV AIDS, 2008	L: A:	English Cost effectiveness,


Cost-Effectiveness Analysis of Enfuvirtide (ENF) Added to an Optimized Therapy vs an Optimized Therapy Alone in Patients With HIV/AIDS.
Author(s): Badia X, Lizan L, Magaz S, Alvarez C, Green J, Serrano D.
Affiliations(s):
Publication(s): HIV Clinical Trials 2007;8(4):235-45
Document Type(s): Manuscript in preparation,
Countries: Spain,
Click here for the abstract
C: Y:	HIV AIDS, 2007	L: A:	English Cost effectiveness,


1 of 2